Ac immune reports full year 2021 financial results and provides corporate update

Seven clinical data readouts expected in 2022 three vaccines, targeting tau, abeta and alpha-synuclein, advancing in 2022 semorinemab phase 2 lauriet trial: additional fluid biomarker data expected in h2 2022 initiation of aci-24 anti-abeta vaccine phase 1b/2 trial in patients with alzheimer's disease (ad) and people living with down syndrome (ds) expected in h1 2022 ad/pd™ conference: aci-12589 identified as a reliable and accurate pet tracer for alpha-synucleinopathies (e.g. msa) strong financial position of chf 198.2 million ensures the company is fully financed through at least q1 2024
ACIU Ratings Summary
ACIU Quant Ranking